Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
New York Genome Center | RCV001420519 | SCV001622820 | uncertain significance | Developmental and epileptic encephalopathy, 18 | 2020-05-29 | criteria provided, single submitter | clinical testing | |
Molecular Genetics, |
RCV003994289 | SCV004812311 | uncertain significance | Early infantile epileptic encephalopathy with suppression bursts | 2023-06-06 | criteria provided, single submitter | clinical testing | This sequence change in SZT2 is predicted to replace valine with leucine at codon 1063, p.(Val1063Leu). Conservation of the valine residue is not assessable (100 vertebrates, UCSC), and it is not located in an annotated functional domain. There is a small physicochemical difference between valine and leucine. The highest population minor allele frequency in the population database gnomAD v3.1 is 0.2% (10/5,178 alleles) in the East Asian population. To our knowledge, this variant has not been previously reported in the relevant scientific literature and has been reported as a variant of uncertain significance (ClinVar ID: 1098584). Computational evidence is unavailable for the missense substitution. Based on the classification scheme RMH Modified ACMG Guidelines v1.6.1, this variant is classified as a VARIANT OF UNCERTAIN SIGNIFICANCE. Following criteria are met: none. |
Prevention |
RCV004749686 | SCV005354452 | likely benign | SZT2-related disorder | 2024-05-09 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |